Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 276

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 276
---
    
 December 31, or (iii) such number of shares of common stock as determined by our board. The number of shares reserved under the 2023        
 ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. As of January            
 8, 2025, the board of directors have granted an aggregate of 61,080 option awards under the 2024 Plan, leaving 408,801 shares reserved      
 for future issuance under the 2024 Plan.                                                                                                    |

<div align='center'>162

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</div>

Certain Relationships and Transactions

Other than the compensation
agreements and other arrangements described under the sections entitled “Executive Compensation” and “Director Compensation” above and the transactions described below, since January 1, 2022, there has not been and there is not currently
proposed, any transaction or series of similar transactions to which we were, or will be, a party in which:

| ● | the amount involved exceeded,                                                                                                    
 or will exceed, $120,000 (or, if less, 1% of the average of our total asset amounts at December 31, 2022 and 2023); and          |
| ● | any director, executive                                                                                                          
 officer, holder of 5% or more of any class of our capital stock or any member of the immediate family of, or entities affiliated 
 with, any of the foregoing persons, had, or will have, a direct or indirect material interest.                                   |

PBAX Relationships and Related Party Transactions

Related Party Loans

In order to finance transaction
costs in connection with the Business Combination, the Sponsor or an affiliate of the Sponsor or certain of PBAX’s officers and
directors may, but are not obligated to, to loan PBAX funds as may be required. On December 13, 2022, PBAX issued an unsecured promissory
note in the principal amount of $1,500,000 (the “Promissory Note”) to the Sponsor, pursuant to which the Sponsor agreed to
loan to the PBAX up to $1,500,000. On December 8, 2023, the Promissory Note was amended to increase the total principal amount to
$1,600,000. At the Closing, an aggregate of approximately $1.55 million that had been borrowed under the Promissory Note was extinguished